Piper Sandler raised the firm’s price target on Silk Road Medical to $20 from $18 and keeps a Neutral rating on the shares. The firm notes the company reported Q1 results that included sales of $48.5M, which came in comfortably ahead of the Street’s $44.7M bogey. Additionally, Silk reaffirmed its full year 2024 revenue guidance of $194M-$198M. Altogether, Piper thought the Q1 print was a step in the right direction, but remains on the sidelines for the time being as it looks for more consistent execution going forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILK:
- Silk Road Medical Reports First Quarter 2024 Financial Results
- Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference
- Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
- Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
- Argus upgrades Silk Road Medical to Buy amid expanding commercial footprint